Morgan Keegan Downgrades HAE To Market Perform, $76 PT

Morgan Keegan has downgraded Haemonetics Corporation HAE from Outperform to Market Perform with a $76 price target.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesPrice TargetAnalyst RatingsHealth CareHealth Care SuppliesMorgan Keegan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!